Comparing the Effects of Multicomponent Exercise on Cardiovascular Health and Lipid Profiles in Premenopausal and Postmenopausal Women

Background: The present study aimed to examine the effects of a 26-week multicomponent exercise program on lipid and lipoprotein profiles, blood pressure, and anthropometric parameters in healthy but sedentary premenopausal and postmenopausal women aged 40-60.

Method: The program, comprising resistance, balance, flexibility, and aerobic exercises, aimed to identify group-specific responses and establish the program's efficacy in mitigating cardiovascular risks. Seventy-five women were recruited, and 38 completed the intervention. Participants were categorized into premenopausal (n=18), postmenopausal (n=10), and control groups (n=10). Key measures included total cholesterol, low- and high-density lipoprotein cholesterol, triglycerides, glucose, systolic and diastolic blood pressure, and anthropometric variables. Statistical analyses employed the Shapiro-Wilk test, paired t-tests, Wilcoxon tests, and Kruskal-Wallis tests, with α=0.05.

Study Overview

• Status: Completed
• Conditions: Menopause; Cardiovascular
• Intervention / Treatment: Other: Experimental: Pre-Menopausic; Other: Experimental: Post- Menopausic

• Study Type: Interventional
• Enrollment (Actual): 75
• Phase: Not Applicable

Contacts and Locations

Study Locations

• Portugal
  • Évora, Portugal
    • Bruno Figueira

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Adult
• Accepts Healthy Volunteers: Yes

Description

Inclusion Criteria:

• women aged between 40 and 60 years old;
• healthy, asymptomatic, and non-smoking;
• medical diagnosis favouring the engagement in physical-sporting activities;
• absence of clinical history related to alcoholism or uncontrolled metabolic disease;
• no clinical prescription for hypotensive pharmacological intake, cholesterol reduction, hormonal replacement therapy, or any other intervention capable of inducing alterations in lipid and lipoprotein metabolism; or
• abnormal blood sample results.

Exclusion Criteria:

• non-fulfilment of inclusion criteria;
• clinical history characterized by symptoms related to cardiovascular disease (CVD), including stroke (CVA) and coronary vascular disease (CVD), renal or hepatic disease, musculoskeletal disorders, or rheumatoid conditions that may impede full participation in the exercise program.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Other
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: Single

Number of Arms

3

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
No Intervention: Control
Experimental: Pre-Menopausic	Other: Experimental: Pre-Menopausic; The physical exercise program, lasting for 26 weeks, was conducted with an uninterrupted weekly frequency of 3 sessions, on non-consecutive days, in the late afternoon (at 7:30 PM), each lasting 60 minutes.
Experimental: Post- Menopausic	Other: Experimental: Post- Menopausic; The physical exercise program, lasting for 26 weeks, was conducted with an uninterrupted weekly frequency of 3 sessions, on non-consecutive days, in the late afternoon (at 7:30 PM), each lasting 60 minutes.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Time Frame
Total Cholesterol	26-week
Low-density lipoprotein Cholesterol	26-week
High-density lipoprotein Cholesterol	26-week
Triglycerides	26-week
Castelli Risk Index I	26-week
Castelli Risk Index II	26-week
Very Low-Density Lipoprotein Cholesterol	26-week
Glucose	26-week
Systolic Blood Pressure	26-week
Diastolic Blood Pressure	26-week
Heart Rate	26-week
Body Mass Index	26-week
Waist Circumference	26-week
Hip Circumference	26-week
Waist Circumference/ Hip Circumference	26-week

Collaborators and Investigators

• Sponsor: University of Évora

Study record dates

Study Major Dates

• Study Start (Actual): May 1, 2024
• Primary Completion (Actual): August 1, 2024
• Study Completion (Actual): December 31, 2024

Study Registration Dates

• First Submitted: January 16, 2025
• First Submitted That Met QC Criteria: January 24, 2025
• First Posted (Actual): March 25, 2025

Study Record Updates

• Last Update Posted (Actual): March 25, 2025
• Last Update Submitted That Met QC Criteria: January 24, 2025
• Last Verified: January 1, 2025

More Information

Terms related to this study

• Other Study ID Numbers: 22137 (Other Identifier: City of Hope Medical Center)

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No